Should I buy or sell Viracta Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIRX shares. View VIRX analyst ratings or view top-rated stocks .

What is Viracta Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for Viracta Therapeutics' stock. Their VIRX share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 717.1% from the stock's current price. View analysts price targets for VIRX or view top-rated stocks among Wall Street analysts .

How have VIRX shares performed in 2024?

Viracta Therapeutics' stock was trading at $0.57 on January 1st, 2024. Since then, VIRX shares have increased by 50.3% and is now trading at $0.8567. View the best growth stocks for 2024 here .

When is Viracta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our VIRX earnings forecast .

How were Viracta Therapeutics' earnings last quarter?

Viracta Therapeutics, Inc. (NASDAQ:VIRX) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05.

How do I buy shares of Viracta Therapeutics?

Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

→ Chances are you know the firms on this list (From WealthPress) (Ad)

Free VIRX Stock Alerts

$0.86

-0.05 (-5.51%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.82
▼
$0.91
50-Day Range: $0.62
▼
$1.17
52-Week Range: $0.43
▼
$2.38

Volume: 52,613 shs
Average Volume: 112,803 shs
Market Capitalization: $33.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Viracta Therapeutics alerts:

Viracta Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 717.1% Upside
$7.00 Price Target
Short Interest: Bearish
2.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.06
Based on 9 Articles This Week
Insider Trading: Selling Shares
$2,486 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.28) to ($1.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.19 out of 5 stars

Medical Sector

753rd out of 911 stocks

Pharmaceutical Preparations Industry

334th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Viracta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Viracta Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.37% of the float of Viracta Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Viracta Therapeutics has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Viracta Therapeutics has recently increased by 2.16%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Viracta Therapeutics does not currently pay a dividend.
Dividend Growth
Viracta Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIRX.

1.1

News and Social Media Coverage

News Sentiment
Viracta Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Viracta Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for VIRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Viracta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viracta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,486.00 in company stock.
Percentage Held by Insiders
Only 7.42% of the stock of Viracta Therapeutics is held by insiders.
Percentage Held by Institutions
Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Viracta Therapeutics are expected to grow in the coming year, from ($1.28) to ($1.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viracta Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viracta Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viracta Therapeutics has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

VIRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VIRX Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Promising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeutics

April 18, 2024 | americanbankingnews.com

Viracta Therapeutics (NASDAQ:VIRX) Given "Outperform" Rating at Oppenheimer

April 20, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

April 17, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)

April 17, 2024 | americanbankingnews.com

Viracta Therapeutics (NASDAQ:VIRX) Receives Buy Rating from HC Wainwright

April 16, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)

April 15, 2024 | msn.com

Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?

April 15, 2024 | globenewswire.com

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

April 20, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

April 1, 2024 | globenewswire.com

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

March 22, 2024 | investing.com

Viracta Therapeutics CFO and COO Dan Chevallard resigns

March 12, 2024 | markets.businessinsider.com

Buy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financials

March 8, 2024 | msn.com

VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023

March 7, 2024 | globenewswire.com

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 29, 2024 | globenewswire.com

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

February 17, 2024 | finance.yahoo.com

VIRX Mar 2024 2.500 call

February 6, 2024 | finance.yahoo.com

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 4, 2024 | finance.yahoo.com

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

December 22, 2023 | benzinga.com

Viracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and Dates

December 12, 2023 | msn.com

Viracta gets orphan drug status for Nana-val for EBV tumors

December 12, 2023 | finance.yahoo.com

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

December 4, 2023 | finance.yahoo.com

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

November 18, 2023 | morningstar.com

Viracta Therapeutics Inc VIRX

November 9, 2023 | benzinga.com

Viracta Therapeutics: Q3 Earnings Insights

November 9, 2023 | finance.yahoo.com

Viracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical Advances

November 9, 2023 | finance.yahoo.com

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

October 5, 2023 | markets.businessinsider.com

Promising Developments in Viracta Therapeutics Research and Trials Bolster Buy Rating

See More Headlines

Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VIRX
CUSIP: N/A
CIK: 1061027
Web: www.viracta.com
Phone: (858) 400-8470
Fax: 650-266-3501
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $13.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +717.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -172.32%
Return on Assets: -71.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.43
Quick Ratio: 1.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.33 per share
Price / Book: 2.60

Miscellaneous

Outstanding Shares: 39,270,000
Free Float: 36,358,000
Market Cap: $33.64 million
Optionable: Optionable
Beta: 0.93

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Mark Andrew Rothera (Age 61)
CEO, President & Director
Comp: $365.03k
Dr. Ayman El-Guindy
Chief Scientific Officer
Mr. Stewart M. Brown
Senior VP of Legal Affairs & General Counsel
Ms. Cheryl A. Madsen
Senior Vice President of Regulatory Affairs
Mr. Patric Nelson M.B.A.
Senior Vice President of Business Development & Corporate Strategy
Dr. Darrel P. Cohen M.D.
Ph.D., Chief Medical Officer
Ms. Biljana Nadjsombati Pharm.D.
Senior Vice President of Pharmaceutical Development
Mr. Robert C. McRae
Vice President of Operations & Strategic Alliances

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Viracta Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIRX shares.
View VIRX analyst ratings or view top-rated stocks.
What is Viracta Therapeutics' stock price target for 2024?: 4 Wall Street research analysts have issued twelve-month target prices for Viracta Therapeutics' stock. Their VIRX share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 717.1% from the stock's current price.
View analysts price targets for VIRX or view top-rated stocks among Wall Street analysts.
How have VIRX shares performed in 2024?: Viracta Therapeutics' stock was trading at $0.57 on January 1st, 2024. Since then, VIRX shares have increased by 50.3% and is now trading at $0.8567.
View the best growth stocks for 2024 here.
When is Viracta Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our VIRX earnings forecast.

How were Viracta Therapeutics' earnings last quarter?: Viracta Therapeutics, Inc. (NASDAQ:VIRX) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05.
How do I buy shares of Viracta Therapeutics?: Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIRX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Viracta Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Viracta Therapeutics Stock (NASDAQ:VIRX)

VIRX Stock Price History

VIRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VIRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™